Perigon Wealth Management LLC lifted its stake in shares of Boston Scientific Co. (NYSE:BSX – Free Report) by 4.7% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 8,340 shares of the medical equipment provider’s stock after acquiring an additional 371 shares during the period. Perigon Wealth Management LLC’s holdings in Boston Scientific were worth $417,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Householder Group Estate & Retirement Specialist LLC acquired a new position in shares of Boston Scientific during the 1st quarter valued at $26,000. Asset Dedication LLC raised its holdings in Boston Scientific by 109.5% during the first quarter. Asset Dedication LLC now owns 551 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 288 shares during the last quarter. Hazlett Burt & Watson Inc. raised its holdings in Boston Scientific by 56.7% during the fourth quarter. Hazlett Burt & Watson Inc. now owns 636 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 230 shares during the last quarter. BerganKDV Wealth Management LLC grew its stake in shares of Boston Scientific by 44.3% in the 1st quarter. BerganKDV Wealth Management LLC now owns 658 shares of the medical equipment provider’s stock worth $33,000 after acquiring an additional 202 shares in the last quarter. Finally, Baldwin Brothers LLC MA bought a new stake in shares of Boston Scientific in the 4th quarter worth $34,000. Institutional investors and hedge funds own 92.20% of the company’s stock.
Boston Scientific Price Performance
NYSE BSX opened at $51.69 on Monday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.40 and a quick ratio of 0.89. The stock’s 50-day moving average is $52.57 and its two-hundred day moving average is $50.29. The firm has a market cap of $72.37 billion, a P/E ratio of 86.15, a price-to-earnings-growth ratio of 2.15 and a beta of 0.80. Boston Scientific Co. has a fifty-two week low of $37.74 and a fifty-two week high of $54.74.
Insider Activity
In related news, EVP Eric Francis Yves Thepaut sold 83,401 shares of the company’s stock in a transaction dated Tuesday, May 2nd. The shares were sold at an average price of $52.49, for a total value of $4,377,718.49. Following the transaction, the executive vice president now owns 12,269 shares in the company, valued at approximately $643,999.81. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other Boston Scientific news, EVP Wendy Carruthers sold 11,671 shares of the company’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $53.24, for a total value of $621,364.04. Following the completion of the sale, the executive vice president now directly owns 72,847 shares of the company’s stock, valued at approximately $3,878,374.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Eric Francis Yves Thepaut sold 83,401 shares of the business’s stock in a transaction dated Tuesday, May 2nd. The shares were sold at an average price of $52.49, for a total transaction of $4,377,718.49. Following the completion of the transaction, the executive vice president now owns 12,269 shares in the company, valued at $643,999.81. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 176,779 shares of company stock valued at $9,371,164. 0.53% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
Several research firms have recently issued reports on BSX. Piper Sandler upped their target price on shares of Boston Scientific from $58.00 to $62.00 in a research note on Thursday, July 6th. StockNews.com began coverage on shares of Boston Scientific in a research note on Thursday, May 18th. They issued a “buy” rating on the stock. TheStreet raised shares of Boston Scientific from a “c+” rating to a “b” rating in a research note on Tuesday, May 30th. Oppenheimer raised their target price on shares of Boston Scientific from $58.00 to $59.00 in a report on Friday. Finally, Robert W. Baird initiated coverage on shares of Boston Scientific in a report on Tuesday, July 18th. They issued an “outperform” rating and a $59.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Boston Scientific has an average rating of “Buy” and a consensus target price of $58.20.
Boston Scientific Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.
Further Reading
- Five stocks we like better than Boston Scientific
- How to Invest in Biotech Stocks
- Stepping Up: Skechers’ Strong Q2 Boosts Investor Confidence
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Should a Lack of Windfall Profits Keep You Out on Chevron Stock?
- How to Invest in Renewable Energy
- Two Foolproof Plays for Apple’s Earnings
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
